Yarrow Bioscience closes reverse merger with VYNE, secures $200M financing, and outlines post-merger capital structure and leadership
Summary
Yarrow Bioscience completed its reverse merger with VYNE Therapeutics, emerging with a new ticker (YARW), a $200M financing, and a lead drug candidate in Phase 2 for Graves' disease. The filing details the post-merger capitalization, new leadership, and equity plans.
Key Events · M&A and Partnerships · VYNE
-
Reverse Merger Closed
The merger between VYNE Therapeutics and Yarrow Bioscience closed on July 27, 2026. Pre-merger Yarrow stockholders now own approximately 97% of the combined company, which trades under the ticker YARW on Nasdaq.
-
Post-Merger Capitalization
Immediately following the merger, the company has approximately 2,803,078 shares of common stock outstanding and 25,781,230 pre-funded warrants, totaling about 28.6 million shares on a fully-diluted basis (excluding equity plans). The pre-funded warrants are exercisable at $0.0001 per share.
-
$200M Financing Completed
The company completed pre-closing private placements totaling approximately $200 million in gross proceeds, including a $100 million Series A preferred financing and a $100 million common stock/pre-funded warrant PIPE. Combined with existing cash, the company expects its cash balance to fund operations into 2028.
-
New Leadership and Governance
Rebecca Frey was appointed CEO, Tyler Zeronda as CFO, and a new six-member board was installed, including Bill Lundberg as Chair. The company adopted new equity incentive plans (2026 Stock Plan with 2.69M shares, 2026 ESPP with 0.34M shares) and entered into amended employment agreements with the CEO and COO.
Analysis · VYNE · Life Sciences
The reverse merger between VYNE Therapeutics and Yarrow Bioscience closed on July 27, 2026, creating a combined company focused on autoimmune thyroid diseases. For the first time, the 8-K details the post-merger capitalization: approximately 2.8 million shares outstanding plus 25.8 million pre-funded warrants, yielding a fully-diluted share count of about 28.6 million (excluding equity plans). New executive employment agreements were disclosed for CEO Rebecca Frey and COO Rachael Alford, alongside the adoption of fresh equity incentive plans and the appointment of a new board and management team. The filing confirms the combined company holds approximately $118.7 million in cash, expected to fund operations into 2028, and highlights upcoming clinical catalysts for its lead asset YB-101, including Phase 2a data in Graves' disease anticipated in the second half of 2027. This is a transformative event that reshapes the company's capital structure, governance, and strategic direction.
At the time of this filing, VYNE was trading at $28.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.